トップ›研究者一覧›中村文香

研究者を探す

研究者にアプローチする
更新情報を通知する

中村文香

徳島大学

プロフィール
教育活動
研究活動
社会活動
リサーチマップ・
Jグローバル
KAKEN
注目研究

研究者総覧で最新データを確認する

2024年4月26日更新

職名: 特任助教
電話: 研究者総覧に該当データはありませんでした。
電子メール: 研究者総覧に該当データはありませんでした。
学歴: 研究者総覧に該当データはありませんでした。
学位: 学士 (滋賀医科大学)
職歴・経歴: 2018/4: 徳島大学特任助教, 病院 (-2024.3.)

専門分野・研究分野: 研究者総覧に該当データはありませんでした。

研究者総覧で最新データを確認する

2024年4月26日更新

専門分野・研究分野: 研究者総覧に該当データはありませんでした。
担当経験のある授業科目: 研究者総覧に該当データはありませんでした。
指導経験: 研究者総覧に該当データはありませんでした。

研究者総覧で最新データを確認する

2024年4月26日更新

専門分野・研究分野: 研究者総覧に該当データはありませんでした。

研究テーマ: 研究者総覧に該当データはありませんでした。

著書

研究者総覧に該当データはありませんでした。

論文

Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Motoko Sei, Hiroyuki Ueda, reiko yokoyama, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Fumika Nakamura, Tetsu Tomonari, Koichi Okamoto, Yutaka Kawano, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama :
Association of metabolic dysfunction-associated steatotic liver disease with erosive esophagitis development: a longitudinal observational study.,
Journal of Gastroenterology and Hepatology, Vol.Online ahead of print., 2024.

(要約): Although erosive esophagitis (EE) is associated with fatty liver and metabolic dysregulation, the association between EE and metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear. Thus, this study aimed to investigate the longitudinal association between MASLD and EE. We included 1578 patients without EE at baseline who underwent more than two health checkups over 2 years. Generalized estimation equations were used to analyze associations between MASLD and EE according to repeated measures at baseline and most recent stages. EE development rates in men and women were 14.5% and 7.2%, respectively. After adjusting for lifestyle habits, the odds ratios of MASLD for EE development in men and women were 1.907 (95% confidence interval [CI]: 1.289-2.832, P < 0.005) and 1.483 (95% CI: 0.783-2.811, P = 0.227), respectively. In the subgroup analysis, after adjusting for lifestyle habits, among men and women aged ≥50 years with more than three MASLD components, the odds ratios for EE development were 2.408 (95% CI: 1.505-3.855, P < 0.001) and 2.148 (95% CI: 1.093-4.221, P < 0.05), respectively. After adjusting for various factors, the significant risk factors for EE development were different between men and women. The influence of MASLD and other factors on EE development differed by sex and age. Particularly, patients aged ≥50 years with MASLD and with an increased number of MASLD components should be considered at increased risk for EE.
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/jgh.16530
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38419514; ● Search Scopus @ Elsevier (PMID): 38419514; ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.16530

(DOI: 10.1111/jgh.16530, PubMed: 38419514) Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Motoko Sei, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Fumika Nakamura, Tetsu Tomonari, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama :
Association of metabolic dysfunction-associated fatty liver disease with gallstone development: A longitudinal study.,
Journal of Gastroenterology and Hepatology, Vol.Online ahead of print., 2024.

(要約): The influence of metabolic dysfunction-associated fatty liver disease on gallstone development remains unclear. We aimed to investigate the longitudinal association between metabolic dysfunction-associated fatty liver disease and gallstone development in both men and women. This observational cohort study included 5398 patients without gallstones who underwent > 2 health check-ups between April 1, 2014, and March 31, 2020. A generalized estimation equation model was used to analyze the association between metabolic dysfunction-associated fatty liver disease and gallstone development according to repeated measures at baseline and most recent stage. After adjustment, the odds ratios of metabolic dysfunction-associated fatty liver disease for gallstone development in men and women were 3.019 (95% confidence interval [CI]: 1.901-4.794) and 2.201 (95% CI: 1.321-3.667), respectively. Among patients aged ≥ 50 years, the odds ratio for gallstone development was significantly enhanced with increasing metabolic dysfunction-associated fatty liver disease component numbers in both sexes; however, no significance was observed in those aged < 50 years. Other significant risk factors for gallstone development were age (odds ratio: 1.093, 95% CI: 1.060-1.126) and waist circumference (odds ratio: 1.048, 95% CI: 1.018-1.079) in men and age (odds ratio: 1.035, 95% CI: 1.003-1.067) and current smoking (odd ratio: 5.465, 95% CI: 1.881-15.88) in women. Although the risk factors for gallstone development differed between sexes, metabolic dysfunction-associated fatty liver disease was common. Paying attention to an increase in the number of metabolic dysfunction-associated fatty liver disease components in patients aged ≥ 50 years is important for gallstone prevention.
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/jgh.16483
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38212880; ● Search Scopus @ Elsevier (PMID): 38212880; ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.16483

(DOI: 10.1111/jgh.16483, PubMed: 38212880) Reiko Yokoyama, Yasushi Sato, Fumika Nakamura, Kaizo Kagemoto, Yasuhiro Mitsui, Koichi Okamoto, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto and Tetsuji Takayama :
Efficacy of immune checkpoint inhibitors in patients with anorectal melanoma in association with immune-related adverse events: a case series.,
Clinical Journal of Gastroenterology, Vol.Online ahead of print., 2023.

(要約): Anorectal melanoma (AM) is a rare subtype of mucosal melanoma with a poor prognosis. Given its rarity compared to its cutaneous counterpart, the benefits and side effects of immune checkpoint inhibitor (ICI) therapy and the relationship between side effects and prognosis remain unclear. Herein, we describe the clinical presentation of five patients with AM treated with ICI as well as their relationship to the treatment course and the development of immune-related adverse events (irAEs). Three patients received sequential or concurrent administrations of nivolumab and ipilimumab, one received nivolumab alone, and one received ipilimumab alone. The response rate (RR) and disease control rate (DCR) were 40% and 80%, respectively. Pituitary and hepatic dysfunctions were the most common irAEs observed (40% each), followed by thyroid, diarrhea, and renal dysfunctions (20% each). The RR was 67% in patients with irAEs while no response was observed in patients without irAEs. DCR was 100% and 50% in patients with and without irAEs, respectively. Overall survival was 34 months in irAE and 8.75 months in non-irAE cases, with a longer survival trend in irAE cases. ICI therapy was effective and well-tolerated by AM patients, with potentially better outcomes for those who experienced irAEs compared to those who did not.
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s12328-023-01849-z
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37632658; ● Summary page in Scopus @ Elsevier: 2-s2.0-85169147432

(DOI: 10.1007/s12328-023-01849-z, PubMed: 37632658, Elsevier: Scopus) Yoshifumi Kida, Toshiya Okahisa, Yasushi Sato, Masahiro Bando, Shota Fujimoto, ma beibei, Tadahiko Nakagawa, Tomoyuki Kawaguchi, Fumika Nakamura, Koichi Okamoto, Hiroshi Miyamoto, Masahiro Sogabe, Koichi Tsuneyama and Tetsuji Takayama :
Urokinase-type plasminogen activator blockade ameliorates experimental colitis in mice.,
Scientific Reports, Vol.13, No.1, 2899, 2023.

(要約): Although several angiogenesis-related factors are reportedly involved in the pathogenesis of ulcerative colitis (UC), the mechanisms by which they contribute to disease are unclear. We first examined the expression of angiogenesis-related factors in inflamed colorectal tissue of UC patients using antibody array, and identified the 5 factors with highest expression, which included matrix metalloproteinase-8, urokinase-type plasminogen activator (uPA), angiostatin/plasminogen, hepatocyte growth factor and endoglin. Subsequent real-time PCR experiments using additional colorectal tissues revealed that uPA mRNA levels were significantly higher in inflamed tissues than in non-inflamed tissues, and significantly correlated with the severity of UC. Mirror section immunohistochemistry revealed that uPA was expressed in the neutrophils of inflamed colorectal tissues. We administered dextran sulfate sodium (DSS) in drinking water to uPA knockout (uPA) mice, and found that the disease activity index in uPA mice was marginally lower and the histological score in uPA mice was significantly lower than those in wild-type mice, suggesting the importance of uPA in colitis. When an uPA-selective inhibitor, UK122, was administered to DSS-treated C57BL6J mice, the disease activity index and histological score in those mice were significantly lower compared with control mice. Multiple cytokine/chemokine assay using colorectal tissues from uPA and UK122-treated mice revealed significantly lowered level of RANTES. In conclusion, uPA was highly expressed in neutrophils of the inflamed mucosa of UC patients, and the expression level correlated with the severity of UC. Genetic uPA deletion or pharmacological uPA blockade significantly ameliorated colitis in mice, concomitant with downregulation of RANTES.
(キーワード): Animals / Mice / Urokinase-Type Plasminogen Activator / Colitis / Colitis, Ulcerative / Serine Proteases / Colorectal Neoplasms
(徳島大学機関リポジトリ): ● Metadata: 118522
(出版サイトへのリンク): ● Publication site (DOI): 10.1038/s41598-023-29824-1
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36806262; ● Search Scopus @ Elsevier (PMID): 36806262; ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-023-29824-1

(徳島大学機関リポジトリ: 118522, DOI: 10.1038/s41598-023-29824-1, PubMed: 36806262) Fumika Nakamura, Yasushi Sato, Koichi Okamoto, Yasuteru Fujino, Yasuhiro Mitsui, kaizo kagemoto, Tomoyuki Kawaguchi, Hiroshi Miyamoto, Naoki Muguruma, Tomoko Sonoda, Koichi Tsuneyama and Tetsuji Takayama :
Colorectal carcinoma occurring via the adenoma-carcinoma pathway in patients with serrated polyposis syndrome.,
Journal of Gastroenterology, Vol.57, No.4, 286-299, 2022.

(要約): Although serrated polyposis syndrome (SPS) is associated with an increased colorectal cancer (CRC) risk, the carcinogenic mechanisms remain unknown. We investigated clinicopathological characteristics and genetic abnormalities in colorectal polyps and CRC to elucidate carcinogenic mechanisms in SPS. We retrospectively analyzed clinicopathological features of colorectal polyps in 44 SPS patients, and examined mutations of genes including APC, RAS, BRAF, and TP53, and microsatellite instability (MSI) in CRC tissues. Of the 44 patients, 25 (56%) fulfilled WHO criterion 1, 11 (25%) fulfilled criterion 2, and 8 (18%) fulfilled both. A total of 956 polyps were observed; 642 (67%) hyperplastic polyps (HP), 204 (21%) sessile serrated lesions (SSL), 10 (1%) traditional serrated adenoma (TSA), and 100 (11%) adenomas. The median numbers of polyps (/patient) were 10.5 (IQR 2.75-23) HPs, 4.0 (2.0-6.0) SSLs, 0 (0-0) TSA, and 1 (0-3.3) adenoma. SSL and HP located preferentially in the proximal and distal colon, respectively. Twenty-two CRCs were found in 18 patients. Based on the histological coexistence of SSL/TSA, BRAF mutation and MSI, 5 CRCs (26%) were classified as serrated-neoplasia pathway. Conversely, based on the coexistence of adenoma, APC/RAS and TP53 mutations, 11 CRCs (58%) were classified as adenoma-carcinoma pathway. The remaining three were unclassifiable. Most CRCs through adenoma-carcinoma pathway were located in the left-side colorectum and patients bearing those met criterion 2, characterized by many HP and advanced adenomas. Adenoma was a significant risk factor for CRC. Our results suggest that more than half of the CRCs, particularly those in the left-side colorectum, developed through the adenoma-carcinoma pathway in SPS patients. Adenoma was a risk factor for CRCs, suggesting its importance in colorectal carcinogenesis.
(キーワード): Adenoma / Carcinoma / Colonic Polyps / Colorectal Neoplasms / Humans / Intestinal Polyposis / Microsatellite Instability / Mutation / Proto-Oncogene Proteins B-raf / Retrospective Studies
(徳島大学機関リポジトリ): ● Metadata: 117614
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s00535-022-01858-8
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35194694; ● Search Scopus @ Elsevier (PMID): 35194694; ● Search Scopus @ Elsevier (DOI): 10.1007/s00535-022-01858-8

(徳島大学機関リポジトリ: 117614, DOI: 10.1007/s00535-022-01858-8, PubMed: 35194694) Yasutsugu Shimohara, Yuji Urabe, Shiro Oka, Hisabe Takahashi, Atsushi Yamada, Hiro-o Matsushita, Bunichiro Kato, Hirotsugu Sakamoto, Joichiro Horii, Daisuke Watanabe, Hirotsugu Ega, Fumika Nakamura, Akiko Chino, Hironori Yamamoto, Tetsuji Takayama, Takayuki Matsumoto, Hideki Ishikawa and Shinji Tanaka :
Clinicopathological characteristics of colorectal serrated polyposis syndrome (SPS): results of a multicenter study by the SPS Study Group in Japan.,
Journal of Gastroenterology, Vol.57, No.4, 300-308, 2022.

(要約): Serrated polyposis syndrome (SPS), a type of colorectal polyposis characterized by multiple serrated polyps, is associated with a high risk of colorectal carcinoma (CRC). This study aimed to clarify the clinicopathological characteristics of SPS in Japan. We investigated the clinicopathological characteristics of patients with SPS from the "Multicenter Study on Clinicopathological Characteristics of SPS (UMIN 000032138)" by the Colorectal Serrated Polyposis Syndrome (SPS) Study Group. In this study, patients were diagnosed with SPS based on the 2019 World Health Organization (WHO) SPS diagnostic criteria. Ninety-four patients were diagnosed with SPS in 10 institutions between January 2001 and December 2017. The mean number (± standard deviation [SD]) of resected lesions per patient was 11.3 ± 13.8. The mean age at diagnosis of SPS was 63.3 ± 11.6 years, and 58 patients (61.7%) were male. Eighty-seven (92.6%) and 16 (17.0%) patients satisfied WHO diagnostic criteria I and II, respectively. Nine patients (9.6%) satisfied both criteria I and II. Carcinoma (T1-T4) were observed in 21 patients (22.3%) and 24 lesions. Of the 21 patients with CRC, 19 (90.4%) satisfied diagnostic criterion I, 1 (4.8%) satisfied diagnostic criterion II, and 1 (4.8%) satisfied diagnostic criteria I and II. There was no notable difference in the prevalence of CRC among patients who met diagnostic criterion I, II, and both I and II. Patients with SPS have a high risk of CRC and should undergo regular surveillance colonoscopy. Raising awareness of this syndrome is crucial.
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s00535-022-01859-7
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35201414; ● Search Scopus @ Elsevier (PMID): 35201414; ● Search Scopus @ Elsevier (DOI): 10.1007/s00535-022-01859-7

(DOI: 10.1007/s00535-022-01859-7, PubMed: 35201414) 藤野泰輝, 田中久美子, 中村文香, 喜田慶史, 平尾章博, 岡田泰行, 武原正典, 福家慧, 坂東良美, 高山哲治 :
関節リウマチの経過中に発生したリウマトイド血管炎に起因する多発大腸潰瘍の1例.,
Gastroenterological Endoscopy, Vol.63, No.7, 1358-1364, 2021年.

(キーワード): リウマトイド血管炎 / 大腸潰瘍
(出版サイトへのリンク): ● Publication site (DOI): 10.11280/gee.63.1358
(文献検索サイトへのリンク): ● CiNii @ 国立情報学研究所 (CRID): 1390007282525435264; ● Search Scopus @ Elsevier (DOI): 10.11280/gee.63.1358

(DOI: 10.11280/gee.63.1358, CiNii: 1390007282525435264) Jun Okazaki, Toshihito Tanahashi, Yasushi Sato, Jinsei Miyoshi, Tadahiko Nakagawa, Tetsuo Kimura, Hiroshi Miyamoto, Yasuteru Fujino, Fumika Nakamura, Masanori Takehara, beibei ma, Masahiro Bando, Shinji Kitamura, Koichi Okamoto, Naoki Muguruma, Masahiro Sogabe and Tetsuji Takayama :
MicroRNA-296-5p Promotes Cell Invasion and Drug Resistance by Targeting Bcl2-Related Ovarian Killer, Leading to a Poor Prognosis in Pancreatic Cancer.,
Digestion, Vol.101, No.6, 794-806, 2020.

(要約): Pancreatic ductal adenocarcinoma (PDAC) is characterized by aggressive invasion, early metastasis, and resistance to chemotherapy, leading to a poor prognosis. To clarify the molecular mechanism of these malignant characteristics, we performed a genome-wide microRNA (miRNA) array analysis utilizing micro-cancer tissues from patients with unresectable PDAC (stage IV), obtained by endoscopic ultrasound-fine needle aspiration (EUS-FNA). The expression profiles of 2,042 miRNAs were determined using micro-cancer tissues from 13 patients with unresectable PDAC obtained by EUS-FNA. The relationship between individual miRNA levels and overall survival (OS) was analyzed. Possible target genes for miRNAs were bioinformatically analyzed using the online database miRDB. Pancreatic cancer cell lines PANC-1, MIA PaCa-2, and PK-8 were transfected with miRNA mimic or small interfering RNA, and cell invasion, epithelial-mesenchymal transition (EMT), and apoptosis markers were examined. miRNA and mRNA expressions were examined by quantitative polymerase chain reaction. Of 2,042 miRNAs, the 10 that exhibited the lowest correlation coefficient (p 0.005) between miRNA expression level and OS among the patients were identified. The miRDB and expression analysis in cancer cell lines for the 10 miRNAs identified miR-296-5p and miR-1207-5p as biomarkers predictive of shorter survival (p < 0.0005). Bioinformative target gene analysis and transfection experiments with miRNA mimics showed that Bcl2-related ovarian killer (BOK), a pro-apoptotic gene, is a target for miR296-5p in pancreatic cancer cells; transfection of miR-296-5p mimic into PANC-1, MIA PaCa-2, and PK-8 cells resulted in significant suppression of BOK mRNA and protein expression. These transfectants showed significantly higher invasion capability compared with control cells, and knock down of BOK in pancreatic cancer cells similarly enhanced invasion capability. Transfectants of miR-296-5p mimic also exhibited aberrant expression of EMT markers, including vimentin and N-cadherin. Moreover, these transfectants showed a significantly lower apoptosis rate in response to 5-fluorouracil and gemcitabine with a decrease of BOK expression, suggesting a role of miR-296-5p in drug resistance. These results suggest that miR-296-5p is a useful biomarker for a poor prognosis in patients with PDAC, and that the miR-296-5p/BOK signaling axis plays an important role in cell invasion, drug resistance, and EMT in PDACs.
(徳島大学機関リポジトリ): ● Metadata: 114153
(出版サイトへのリンク): ● Publication site (DOI): 10.1159/000503225
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31563901; ● Summary page in Scopus @ Elsevier: 2-s2.0-85072925180

(徳島大学機関リポジトリ: 114153, DOI: 10.1159/000503225, PubMed: 31563901, Elsevier: Scopus) 藤井祥平, 中村文香, 佐藤康史, 岸和弘, 吉田守美子, 三井康裕, 藤野泰輝, 北村晋志, 岡本耕一, 宮本弘志, 六車直樹, 高山哲治 :
胃癌における免疫チェックポイント阻害薬の効果と免疫関連副作用(irAE) との関連性についての検討,
四国医学雑誌, Vol.76, No.3-4, 173-178, 2020年.

(要約): Recently, immune checkpoint inhibitors(ICI)have been approved for use in advanced gastric cancer(AGC)based on the positive results of ATTRACTION‐2 trial in Japan. There has been accumulating evidence that the development of immune-related adverse events(irAE)may be associated with a response to ICI therapy, particularly in lung cancer, although little is known about these correlations in gastrointestinal cancer. To investigate the efficacy and irAE of ICI treatment and their correlation in AGC, we retrospectively examined 29 patients with AGC who received nivolumab therapy in our departments. Among them, 15 patients(52%)developed irAEs including 4 patients(14%)for grade 3 irAEs ; liver dysfunction(n＝2), type 1 diabetes mellitus(n＝2) and adrenal insufficiency(n＝1). The median overall survival was12．0months in the irAE group and 3．25 months in the non-irAE group(p＝0．164), which suggested the relationship between the effects and irAEs in ICI treatment of AGC. Further research is required to understand the implications of irAE characteristics on ICI response in GCA patients.
(キーワード): Immune-checkpoint inhibitors / Gastric cancer / Immune-related adverse events / Nivolumab
(文献検索サイトへのリンク): ● CiNii @ 国立情報学研究所 (CRID): 1050004953486029824

(CiNii: 1050004953486029824) Masanori Takehara, Yasushi Sato, Tetsuo Kimura, Kazuyoshi Noda, Hiroshi Miyamoto, Yasuteru Fujino, Jinsei Miyoshi, Fumika Nakamura, Hironori Wada, Yoshimi Bando, Tetsuya Ikemoto, Mitsuo Shimada, Naoki Muguruma and Tetsuji Takayama :
Cancer-associated Adipocytes Promote Pancreatic Cancer Progression Through SAA1 Expression,
Cancer Science, Vol.111, No.8, 2883-2894, 2020.

(要約): Although pancreatic cancer often invades into peripancreatic adipose tissue, little is known about the cancer-adipocyte interaction. We first investigated the ability of adipocytes to de-differentiate to cancer-associated adipocytes (CAAs) by co-culturing with pancreatic cancer cells. We then examined the effects of CAA-conditioned media (CAA-CM) on the malignant characteristics of cancer cells, the mechanism underlying those effects, and their clinical relevance in pancreatic cancer. When 3T3-L1 adipocytes were co-cultured with pancreatic cancer cells (PANC-1) using Transwell system, adipocytes lost their lipid droplets and morphologically changed to fibroblast-like cells (CAA). Adipocyte-specific marker mRNA levels significantly decreased but those of fibroblast-specific markers appeared, characteristic findings of CAA, as revealed by real-time PCR. When PANC-1 cells were cultured with CAA-CM, significantly higher migration/invasion capability, chemoresistance, and epithelial-mesenchymal transition (EMT) properties were observed compared with control cells. To investigate the mechanism underlying these effects, we performed microarray analysis of PANC-1 cells cultured with CAA-CM, and found 78.5-fold higher expression of SAA1 compared with control cells. When SAA1 gene in PANC-1 cells was knocked down with SAA1 siRNA, migration/invasion capability, chemoresistance, and EMT properties were significantly attenuated compared with control cells. Immunohistochemical analysis on human pancreatic cancer tissues revealed positive SAA1 expression in 46/61 (75.4%). Overall survival in the SAA1-positive group was significantly shorter than in the SAA1-negative group (p=0.013). In conclusion, we demonstrated that pancreatic cancer cells induced de-differentiation in adipocytes toward CAA, and CAA promoted malignant characteristics of pancreatic cancer via SAA1 expression, suggesting that SAA1 is a novel therapeutic target in pancreatic cancer.
(徳島大学機関リポジトリ): ● Metadata: 115328
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/cas.14527
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32535957; ● Summary page in Scopus @ Elsevier: 2-s2.0-85087562532

(徳島大学機関リポジトリ: 115328, DOI: 10.1111/cas.14527, PubMed: 32535957, Elsevier: Scopus) Hironori Tanaka, Koichi Okamoto, Yasushi Sato, Takahiro Tanaka, Tetsu Tomonari, Fumika Nakamura, Yasuteru Fujino, Yasuhiro Mitsui, Hiroshi Miyamoto, Naoki Muguruma, Akinori Morita, Hitoshi Ikushima and Tetsuji Takayama :
Synergistic anti-tumor activity of miriplatin and radiation through PUMA-mediated apoptosis in hepatocellular carcinoma.,
Journal of Gastroenterology, Vol.55, No.11, 1072-1086, 2020.

(要約): The prognosis for patients with unresectable advanced hepatocellular carcinoma (HCC) is poor. Miriplatin is a hydrophobic platinum compound that has a long retention time in lesions after transarterial chemoembolization (TACE). We investigated anti-tumor activity of miriplatin combined with irradiation on HCC cells, and its underlying mechanism of apoptosis. We also analyzed the effectiveness of miriplatin-TACE and radiotherapy for locally advanced HCC. Human HCC cell lines HepG2 and HuH-7 were treated with DPC (active form of miriplatin) and radiation, and synergy was evaluated using a combination index (CI). Apoptosis-related proteins and cell cycles were analyzed by western blotting and flowcytometry. We retrospectively analyzed treatment outcomes in 10 unresectable HCC patients with vascular/bile duct invasion treated with miriplatin-TACE and radiotherapy. DPC or X-ray irradiation decreased cell viability dose-dependently. DPC plus irradiation decreased cell viability synergistically in both cell lines (CI < 1, respectively). Cleaved PARP expression was induced much more strongly by DPC plus irradiation than by each treatment alone. Expression of p53 up-regulated modulator of apoptosis (PUMA) was significantly induced by the combination, and knockdown of PUMA with siRNA significantly decreased apoptosis in both cell lines. DPC plus irradiation caused sub-G1, G2/M, and S phase cell arrest in those cells. The combination of miriplatin-TACE and radiotherapy showed a high response rate for patients with locally advanced HCC despite small number of patients. Miriplatin plus irradiation had synergistic anti-tumor activity on HCC cells through PUMA-mediated apoptosis and cell cycle arrest. This combination may possibly be effective in treating locally advanced HCC.
(徳島大学機関リポジトリ): ● Metadata: 115325
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s00535-020-01705-8
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32666201; ● Summary page in Scopus @ Elsevier: 2-s2.0-85087895196

(徳島大学機関リポジトリ: 115325, DOI: 10.1007/s00535-020-01705-8, PubMed: 32666201, Elsevier: Scopus) Yoshihiko Miyamoto, Naoki Muguruma, Shota Fujimoto, Yasuyuki Okada, Yoshifumi Kida, Fumika Nakamura, Kumiko Tanaka, Tadahiko Nakagawa, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato and Tetsuji Takayama :
Epidermal growth factor receptortargeted molecular imaging of colorectal tumors: Detection and treatment evaluation of tumors in animal models.,
Cancer Science, Vol.110, No.6, 1921-1930, 2019.

(要約): To overcome the problem of overlooking colorectal tumors, a new and highly sensitive modality of colonoscopy is needed. Moreover, it is also important to establish a new modality to evaluate viable tumor volume in primary lesions of colorectal cancer (CRC) during chemotherapy. Therefore, we carried out molecular imaging of colorectal tumors targeting epidermal growth factor receptor (EGFR), which is highly expressed on tumor cells, for evaluating chemotherapeutic efficacy and for endoscopic detection of colorectal adenomas. We first attempted to image five CRC cell lines with various levels of EGFR expression using an Alexa Fluor-labeled anti-EGFR monoclonal antibody (AF-EGFR-Ab). A strong fluorescence signal was observed in the cells depending on the level of EGFR expression. When nude mice xenografted with LIM1215 CRC cells, which highly express EGFR, were i.v. injected with AF-EGFR-Ab, a strong fluorescence signal appeared in the tumor with a high signal to noise ratio, peaking at 48 hours after injection and then gradually decreasing, as shown using an IVIS Spectrum system. When the xenografted mice were treated with 5-fluorouracil, fluorescence intensity in the tumor decreased in proportion to the viable tumor cell volume. Moreover, when the colorectum of azoxymethane-treated rats was observed using a thin fluorescent endoscope with AF-EGFR-Ab, all 10 small colorectal adenomas (3 mm) were detected with a clear fluorescence signal. These preliminary results of animal experiments suggest that EGFR-targeted fluorescent molecular imaging may be useful for quantitatively evaluating cell viability in CRC during chemotherapy, and also for detecting small adenomas using a fluorescent endoscope.
(キーワード): Animals / Antineoplastic Agents / Azoxymethane / Cell Line, Tumor / Cell Survival / Colorectal Neoplasms / ErbB Receptors / 女性 (female) / Fluorouracil / HT29 Cells / Humans / 男性 (male) / Mice, Inbred BALB C / Mice, Nude / Molecular Targeted Therapy / Rats, Inbred F344 / Xenograft Model Antitumor Assays
(徳島大学機関リポジトリ): ● Metadata: 113790
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/cas.14020
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30973663; ● Summary page in Scopus @ Elsevier: 2-s2.0-85066789077

(徳島大学機関リポジトリ: 113790, DOI: 10.1111/cas.14020, PubMed: 30973663, Elsevier: Scopus) Hiroshi Miyamoto, Kumiko Tanaka, Fumika Nakamura, Takahiro Ikeda, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Masahiro Sogabe, Naoki Muguruma, Yoshimi Bando and Tetsuji Takayama :
Massive hemobilia following plastic stent removal in common bile duct cancer associated with primary sclerosing cholangitis (with video).,
Clinical Journal of Gastroenterology, Vol.12, No.1, 2019.

(要約): Hemobilia is defined as bleeding into the biliary tract. Herein, we report a very rare case of massive hemobilia following plastic stent (PS) removal in common bile duct (CBD) cancer. A 72-year-old man with primary sclerosing cholangitis had undergone repeated insertion of a PS into the CBD. Biliary tract biopsy was performed based on suspicion of combined CBD cancer. Biopsy revealed poorly differentiated adenocarcinoma of the CBD. One month after the biliary tract biopsy, he was admitted for acute cholangitis, and endoscopic retrograde cholangiography was performed for the exchange of the PS. When one of the two biliary PSs was removed, spurting bleeding from the major papilla began abruptly. The massive bleeding caused the patient to be in a pre-shock state. A retrieval balloon catheter was compressed against the papilla for hemostasis. Although he was treated conservatively, the patient developed a bloody discharge. Upper gastrointestinal endoscopy revealed that the pulsatile bleeding beside the PSs started immediately after the removal of the coagula. Emergent contrast-enhanced computed tomography showed right hepatic artery aneurysm across the CBD. Therefore, transarterial embolization was performed. The patient's post-therapeutic course was uneventful. He received chemotherapy, but died about a half year after hemobilia occurred.
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s12328-018-0888-7
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30056613; ● Summary page in Scopus @ Elsevier: 2-s2.0-85050721343

(DOI: 10.1007/s12328-018-0888-7, PubMed: 30056613, Elsevier: Scopus) Yuri Matsumoto, Hiroshi Miyamoto, Akira Fukuya, Fumika Nakamura, Takahiro Goji, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Masahiro Sogabe, Naoki Muguruma, Mitsuo Shimada, Yoshimi Bando and Tetsuji Takayama :
Hemosuccus pancreaticus caused by a mucinous cystic neoplasm of the pancreas.,
Clinical Journal of Gastroenterology, Vol.10, No.2, 185-190, 2017.

(要約): Hemosuccus pancreaticus is a gastrointestinal hemorrhage through the main pancreatic duct. Here, we report a rare case of hemosuccus pancreaticus due to a mucinous cystic neoplasm of the pancreas. A 62-year-old woman who had been followed for a branch duct intraductal papillary mucinous neoplasm visited our emergency room due to severe abdominal pain and bloody discharge. Computed tomography revealed that the pancreatic cyst increased the tension of the wall and a high-density area indicative of bleeding into the cyst was observed. Endoscopy showed opening of and hemorrhaging from the papilla of Vater. The patient was diagnosed with hemosuccus pancreaticus caused by hemorrhaging into the cyst from the branch duct intraductal papillary mucinous neoplasm. Based on this diagnosis, elective distal pancreatectomy was performed. The histopathological diagnosis was a mucinous cystic neoplasm with intermediate-grade dysplasia based upon the pathological findings that fibrous ovarian-type stroma existed abundantly and the stroma cells were positive for progesterone receptor and inhibin. Hemosuccus pancreaticus caused by a mucinous cystic neoplasm is extremely rare and there has been only one case reported to date. In conclusion, it should be recognized that pancreatic cystic neoplasms including mucinous cystic neoplasms may cause hemosuccus pancreaticus.
(キーワード): Ampulla of Vater / 女性 (female) / Gastrointestinal Hemorrhage / Humans / 磁気共鳴映像法 (magnetic resonance imaging) / Middle Aged / Neoplasms, Cystic, Mucinous, and Serous / Pancreatic Cyst / Pancreatic Ducts / Pancreatic Neoplasms / Tomography, X-Ray Computed
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s12328-016-0711-2
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28054178; ● Summary page in Scopus @ Elsevier: 2-s2.0-85008158342

(DOI: 10.1007/s12328-016-0711-2, PubMed: 28054178, Elsevier: Scopus) Shinji Kitamura, Naoki Muguruma, Koichi Okamoto, Fumika Nakamura, Yasuyuki Okada, Tetsuo Kimura, Hiroshi Miyamoto and Tetsuji Takayama :
Endoscopic submucosal dissection through a gastrostomy for early gastric cancer in patients with pharyngeal stenosis.,
Gastrointestinal Endoscopy, Vol.79, No.2, 206-207, 2014.

(出版サイトへのリンク): ● Publication site (DOI): 10.1016/j.gie.2013.09.018
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24129250; ● Summary page in Scopus @ Elsevier: 2-s2.0-84892564534

(DOI: 10.1016/j.gie.2013.09.018, PubMed: 24129250, Elsevier: Scopus)

MISC

研究者総覧に該当データはありませんでした。

総説・解説

Yasushi Sato, Koichi Okamoto, Tomoyuki Kawaguchi, Fumika Nakamura, Hiroshi Miyamoto and Tetsuji Takayama :
Treatment Response Predictors of Neoadjuvant Therapy for Locally Advanced Gastric Cancer: Current Status and Future Perspectives.,
Biomedicines, Vol.10, No.7, 1614, Jul. 2022.

(要約): Neoadjuvant chemotherapy (NAC) for locally advanced gastric cancer (LAGC) has been recognized as an effective therapeutic option because it is expected to improve the curative resection rate by reducing the tumor size and preventing recurrence of micrometastases. However, for patients resistant to NAC, not only will operation timing be delayed, but they will also suffer from side effects. Thus, it is crucial to develop a comprehensive strategy and select patients sensitive to NAC. However, the therapeutic effect of NAC is unpredictable due to tumor heterogeneity and a lack of predictive biomarkers for guiding the choice of optimal preoperative treatment in clinical practice. This article summarizes the related research progress on predictive biomarkers of NAC for gastric cancer. Among the many investigated biomarkers, metabolic enzymes for cytotoxic agents, nucleotide excision repair, and microsatellite instability, have shown promising results and should be assessed in prospective clinical trials. Noninvasive liquid biopsy detection, including miRNA and exosome detection, is also a promising strategy.
(徳島大学機関リポジトリ): ● Metadata: 117415
(出版サイトへのリンク): ● Publication site (DOI): 10.3390/biomedicines10071614
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35884916; ● Search Scopus @ Elsevier (PMID): 35884916; ● Search Scopus @ Elsevier (DOI): 10.3390/biomedicines10071614

(徳島大学機関リポジトリ: 117415, DOI: 10.3390/biomedicines10071614, PubMed: 35884916)

講演・発表

Yoshifumi Kida, Toshiya Okahisa, Yasushi Sato, Masahiro Bando, shota fujimoto, Tadahiko Nakagawa, Tomoyuki Kawaguchi, Fumika Nakamura, Koichi Okamoto, Hiroshi Miyamoto, Masahiro Sogabe, Koichi Tsuneyama and Tetsuji Takayama :
Thepapeutic strategy of Ulcerative Colitis targeting Urokinase-type Plasminogen Activator.,
DDW2023, May 2023. Tetsuji Takayama, Yoshifumi Kida, Toshiya Okahisa, Yasushi Sato, Masahiro Bando, shota Fujimoto, Tomoyuki Kawaguchi, Fumika Nakamura, Koichi Okamoto, Hiroshi Miyamoto, Koichi Tsuneyama and Masahiro Sogabe :
The relevance of urokinase-type plasminogen activator in pathogenesis of ulcerative colitis.,
WCOG2022 (World Congress of Gastroenterology), Dubai, Dec. 2022. Yasutsugu Shimohata, Yuji Urabe, Shiro Oka, Takashi Hisabe, Atsushi Yamada, Hiro-O Matsushita, Hirotsugu Sakamoto, Joichiro Horii, Daisuke Watanabe, Hirotsugu Eda, Fumika Nakamura, Hironori Yamamoto, Tetsuji Takayama, Takayuki Matsumoto, Shinji Tanaka and Hideki Ishikawa :
Clinicopathological Characteristics of Serrated Polyposis Syndrome: Results of a Multicenter Study by the Colorectal Serrated Polyposis Syndrome (SPS) Study Group in Japan.,
Digestive Disease Week2021, May 2021. Yasushi Sato, Kumiko Tanaka, Ishikawa Hideki, Satoshi Teramae, Fumika Nakamura, Yasuhiro Mitsui, Kagemoto Kaizo, Hiroshi Miyamoto, Koichi Okamoto, Naoki Muguruma, Ohmiya Naoki, Mutoh Michihiro and Tetsuji Takayama :
Small- intestinal involvement in familial adenomatous polyposis: characteristics and genotype- phenotype correlation from a Japanese cohort study,
DDW, May 2020. Naoki Muguruma, Daisaku Fujimot, Tomoyuki Kawaguchi, Kaizoh Kagemoto, Satoshi Teramae, Yoshifumi Kida, Hironori Wada, Fumika Nakamura, Yasuteru Fujino, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Toshihito Tanahashi, Hiroshi Miyamoto, Yasushi Sato and Tetsuji Takayama :
Linked Color Imaging Improves Detection Rate of Sessile Serrated Adenoma/Polyp in the Colon: A Prospective Randomized Controlled Trial.,
UEG Week 2019, Barcelona, Oct. 2019. Shinji Kitamura, Mototsugu Kato, Kenro Kawada, Masanori Takehara, Kaizo Kagemoto, Fumika Nakamura, Hironori Wada, Naoki Muguruma, Osamu Dohi, Shoko Ono, Hideki Ishikawa and Tetsuji Takayama :
Linked Color Imaging for the Detection of Gastric Neoplasm in High Risk Patients: A Prospective Multicenter Randomized Controlled Trial (LCI-FIND Trial).,
UEG Week2019, Barcelona, Oct. 2019. Hironori Tanaka, Tetsu Tomonari, Takahiro Tanaka, Akihiro Hirao, Fumika Nakamura, Kumiko Tanaka, Koichi Okamoto, Yasushi Sato, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama :
Therapeutic efficacy of chemoradiotherapy with Miriplatin for hepatocellular carcinoma.,
digestive disease week2019, San Diego, May 2019. Jinsei Miyoshi, Noriaki Murayama, Kumiko Tanaka, Takahiro Tanaka, Fumika Nakamura, Yasuteru Fujino, Keiichiro Matsumura, Miwako Kagawa, Tetsu Tomonari, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama :
Development of a Novel Mirna-Based Signature to Predict Invasion and Metastasis in Rectal Neuroendocrine Tumors.,
digestive disease week2019, Vol.156, No.6, 133, San Diego, May 2019.

(出版サイトへのリンク): ● Publication site (DOI): 10.1016/S0016-5085(19)37123-9
(文献検索サイトへのリンク): ● Search Scopus @ Elsevier (DOI): 10.1016/S0016-5085(19)37123-9

(DOI: 10.1016/S0016-5085(19)37123-9) Jun Okazaki, Toshihito Tanahasi, Yasushi Sato, Jinsei Miyoshi, Tadahiko Nakagawa, Tetsuo Kimura, Hiroshi Miyamoto, Yasuteru Fujino, Fumika Nakamura, Masanori Takehara, Masahiro Bando, Shinji Kitamura, Koichi Okamoto, Naoki Muguruma, Masahiro Sogabe and Tetsuji Takayama :
Interaction Between Pancreatic Cancer Cells and Adipocytes Promote Pancreatic Cancer Progression Through Overexpression of Saa1.,
digestive disease week2019, San Diego, May 2019. Tetsuji Takayama, Toshihito Tanahashi, Koichi Okamoto, Shota Fujimoto, Tadahiko Nakagawa, Kaizoh Kagemoto, Yasuyuki Okada, Fumika Nakamura, Yasuteru Fujino, Shinji Kitamura, Hiroshi Miyamoto, Yasushi Sato and Naoki Muguruma :
S100P as a novel hypomethylation target in Sessile Serrated Adenoma(SSA/P)-cancer sequence: A genome-wide DNA methylation array analysis.,
UEG Week2018, Wien, Oct. 2018. Fumika Nakamura, Koichi Okamoto, Kumiko Tanaka, Yasuteru Fujino, Jinsei Miyoshi, Shinji Kitamura, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama :
Clinicopathological Analyses of Colorectal Polyps and Cancers in Serrated Polyposis Syndrome.,
DIgestive Disease Week2018, Washington, D.C., Jun. 2018. Daisaku Fujimoto, Kaizo Kagemoto, Yasuyuki Okada, Hironori Tanaka, Satoshi Teramae, Akihiro Hirao, Fumika Nakamura, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama :
Usefulness of Linked Color Imaging System in Endoscopic Diagnosis of Sessile Serrated Adenoma/Polyp: A Novel Image Enhanced Technique.,
Digestive Disease Week2017, Chicago, May 2017. 横山怜子, 中村文香, 藤本将太, 樫原孝典, 曽我部正弘, 佐藤康史, 高山哲治 :
直腸原発悪性黒色腫に対する免疫チェックポイント阻害剤の有効性と免疫関連副作用の関連性.,
第20回日本消化管学会総会学術集会, 2024年2月. 岡本耕一, 勢井萌都子, 藤本将太, 三橋威志, 吉本貴則, 川口智之, 影本開三, 喜田慶史, 三井康裕, 中村文香, 佐藤康史, 高山哲治 :
Serrated polyposis syndromeの右側及び左側大腸病変の臨床病理学的および分子生物学的解析,
第10回消化管ポリポーシス研究会, 2024年1月. 横山怜子, 佐藤康史, 中村文香, 川口智之, 影本開三, 喜田慶史, 三井康裕, 藤野泰輝, 岡本耕一, 河野豊, 宮本弘志, 高山哲治 :
直腸悪性黒色腫に対する免疫チェックポイント阻害剤の効果予測因子としての irAE の意義.,
第 61 回日本癌治療学会学術集会, 2023年10月. 大木元彩夏, 岡本耕一, 高橋叡, 藤本将太, 吉本貴則, 三橋威志, 川口智之, 影本開三, 喜田慶史, 三井康裕, 中村文香, 佐藤康史, 高山哲治 :
内視鏡による積極的大腸ポリープ摘除術を施行しているリンチ症候群の一例.,
第5回がんゲノム医療時代におけるLynch症候群研究会学術集会, 2023年8月. 岡本耕一, 中村文香, 高山哲治 :
Serrated polyposis syndromeに合併した左側および右側大腸腺腫の臨床病理学的特徴.,
第109回日本消化器病学会総会, 2023年4月. 上田浩之, 川口智之, 和田浩典, 中村文香, 北村晋志, 岡本耕一, 佐藤康史, 高山哲治 :
右側大腸癌における TIMP1 の予後不良因子としての意義:右側及び左側大腸癌を比較して.,
第19回日本消化管学会総会学術集会, 2023年2月. 岡本耕一, 中村文香, 八木麻衣, 岡田明子, 藤井祥平, 吉本貴則, 横山怜子, 川口智之, 影本開三, 喜田慶史, 三井康裕, 佐藤康史, 高山哲治 :
Serrated polyposis syndrome に合併した大腸腺腫の臨床病理学的特徴.,
第98回大腸癌研究会学術集会, 2023年1月. 影本開三, 中村文香, 岡本耕一, 吉本貴則, 川口智之, 横山怜子, 喜田慶史, 三井康裕, 北村晋志, 宮本弘志, 佐藤康史, 高山哲治 :
鋸歯状ポリポーシス症候群における大腸腫瘍の病理像と発癌機序についての解析.,
第60回癌治療学会学術集会, 2022年10月. 中村文香, 岡本耕一, 影本開三, 平田圭市郎, 吉本貴則, 横山怜子, 川口智之, 喜田慶史, 三井康裕, 田中久美子, 北村晋志, 佐藤康史, 高山哲治 :
Serrated polyposis syndromeにおける発癌リスクとその予防.,
第29回日本がん予防学会総会, 2022年7月. 岡本耕一, 中村文香, 高山哲治 :
Serrated polyposis syndromeに合併した左側及び右側大腸癌の臨床病理学的特徴ならびに発癌機序の解析,
第108回日本消化器病学会総会, 2022年4月. 田中宏典, 友成哲, 影本開三, 岡田泰行, 和田浩典, 中村文香, 北村晋志, 岡本耕一, 宮本弘志, 佐藤康史, 六車直樹, 高山哲治 :
免疫チェックポイント阻害薬投与中の肝障害.,
第59回日本癌治療学会学術集会, 2021年10月. 矢野庄悟, 中村文香, 佐藤康史, 福家慧, 藤野泰輝, 北村晋志, 岡本耕一, 宮本弘志, 六車直樹, 高山哲治 :
消化管悪性腫瘍における免疫チェックポイント阻害薬の効果と免疫関連副作用の関連性について.,
第17回日本消化管学会総会学術集会, 2021年2月. 中村文香, 岡本耕一, 影本開三, 喜田慶史, 田中久美子, 北村晋志, 佐藤康史, 宮本弘志, 六車直樹, 高山哲治 :
Serrated polyposis syndrome に合併した大腸癌の臨床病理学的特徴ならびに発癌機序の検討.,
第17回日本消化管学会総会学術集会, 2021年2月. 中村文香, 影本開三, 高山哲治 :
Serrated polyposis syndromeにおける癌の発症リスクと発癌機序の検討.,
第28回消化器関連学会週間(JDDW2020), 2020年11月. 横山怜子, 中村文香, 佐藤康史, 岸和弘, 和田浩典, 友成哲, 北村晋志, 岡本耕一, 宮本弘志, 六車直樹, 岡久稔也, 高山哲治 :
胃癌におけるICI治療の効果予測因子としてのirAEの意義とその後治療への影響.,
第58回日本癌治療学会学術集会, 2020年10月. 藤井祥平, 中村文香, 佐藤康史, 岸和弘, 吉田守美子, 三井康裕, 藤野泰輝, 北村晋志, 岡本耕一, 宮本弘志, 六車直樹, 高山哲治 :
<第23回若手奨励賞>胃癌における免疫チェックポイント阻害薬の効果と免疫関連副作用(irAE)との関連性についての検討.,
四国医学雑誌, Vol.76, No.3-4, 173-178, 2020年8月.

(要約): Recently, immune checkpoint inhibitors(ICI)have been approved for use in advanced gastric cancer(AGC)based on the positive results of ATTRACTION‐2 trial in Japan. There has been accumulating evidence that the development of immune-related adverse events(irAE)may be associated with a response to ICI therapy, particularly in lung cancer, although little is known about these correlations in gastrointestinal cancer. To investigate the efficacy and irAE of ICI treatment and their correlation in AGC, we retrospectively examined 29 patients with AGC who received nivolumab therapy in our departments. Among them, 15 patients(52%)developed irAEs including 4 patients(14%)for grade 3 irAEs ; liver dysfunction(n＝2), type 1 diabetes mellitus(n＝2) and adrenal insufficiency(n＝1). The median overall survival was12．0months in the irAE group and 3．25 months in the non-irAE group(p＝0．164), which suggested the relationship between the effects and irAEs in ICI treatment of AGC. Further research is required to understand the implications of irAE characteristics on ICI response in GCA patients.
(キーワード): Immune-checkpoint inhibitors / Gastric cancer / Immune-related adverse events / Nivolumab
(文献検索サイトへのリンク): ● CiNii @ 国立情報学研究所 (CRID): 1050004953486029824

(CiNii: 1050004953486029824) 樫原孝典, 宮本佳彦, 藤本将太, 和田浩典, 川口智之, 喜田慶史, 中村文香, 田中久美子, 北村晋志, 岡本耕一, 宮本弘志, 佐藤康史, 六車直樹, 高山哲治 :
大腸腫瘍に発現するepidermal growth factor receptor in colorectal tumors.,
第16回日本消化管学会総会学術集会, 2020年2月. 中村文香, 岡本耕一, 影本開三, 田中久美子, 藤野泰輝, 北村晋志, 宮本弘志, 佐藤康史, 六車直樹, 高山哲治 :
Serrated polyposis syndrome の臨床病理学的特徴ならびに発癌機序の検討.,
第16回日本消化管学会総会学術集会, 2020年2月. 川口智之, 武原正典, 影本開三, 寺前智史, 中村文香, 田中貴大, 北村晋志, 岡本耕一, 宮本弘志, 佐藤康史, 六車直樹, 高山哲治 :
胸腺を含む5臓器にわたって10個の同時性多発重複癌を呈したLynch症候群の一例 .,
第57回日本癌治療学会学術集会, 2019年10月. Hironori Tanaka, Koichi Okamoto, 岡田泰行, 宮本佳彦, Yasuhiro Mitsui, Fumika Nakamura, Jinsei Miyoshi, Yasuteru Fujino, Takahiro Tanaka, Tetsu Tomonari, Shinji Kitamura, Hiroshi Miyamoto, Naoki Muguruma, Yasushi Sato and Tetsuji Takayama :
Therapeutic efficacy of miriplatin in combination with radiotherapy for advanced hepatocellular carcinoma.,
第17回日本臨床腫瘍学会学術集会, Jul. 2019. 中村文香, 佐藤康史, 高山哲治 :
消化管腫瘍における免疫チェックポイント阻害薬の自己免疫疾患関連副作用(irAE)の経験,
第26回日本消化器関連学会週間(統合プログラム), 2018年11月. 岩佐一秀, 井形直紀, 本多哲也, 水谷太郎, 西岡潤司, 曽我部正弘, 岡久稔也, 大櫛聖子, 高岡慶史, 岡田泰行, 宮本佳彦, 田中久美子, 中村文香, 宮城愛, 香川美和子, 北村晋志, 北村晋志, 岡本耕一, 高山哲治 :
潰瘍性大腸炎での内視鏡画像解析による大腸粘膜の炎症評価.,
第56回日本人工臓器学会大会, 2018年11月. 和田浩典, 北村晋志, 中村文香, 福家慧, 武原正典, 岡田泰行, 三井康裕, 三好人正, 藤野泰輝, 田中久美子, 岡本耕一, 宮本弘志, 佐藤康史, 六車直樹, 高山哲治 :
CRT後咽頭狭窄を伴う表在型食道癌に対して細径内視鏡を用いたPDTが有効であった一例.,
第56回日本癌治療学会学術集会, 2018年10月. 寺前智史, 田中久美子, 三橋威志, 三井康裕, 中村文香, 藤野泰輝, 三好人正, 北村晋志, 岡本耕一, 宮本弘志, 佐藤康史, 六車直樹, 高山哲治 :
新規APC遺伝子変異(C.1626+1G>A)を認めた家族性大腸腺腫症の一例.,
第6回日本家族性大腸腺腫症研究会学術集会, 2018年9月. 武原正典, 佐藤康史, 津保友香, 福家慧, 岡田泰行, 宮本佳彦, 三井康裕, 藤野泰輝, 中村文香, 北村晋志, 岡本耕一, 宮本弘志, 六車直樹, 高山哲治 :
膵癌と脂肪細胞の相互作用はSAA1の発現を誘導することにより膵癌の浸潤を促進させる.,
第16回日本臨床腫瘍学会学術集会, 2018年7月. 津保友香, 三井康裕, 福家慧, 武原正典, 岡田泰行, 三好人正, 藤野泰輝, 中村文香, 田中久美子, 北村晋志, 岡本耕一, 宮本弘志, 佐藤康史, 六車直樹, 高山哲治 :
切除不能進行神経内分泌癌に対するIrinotecan+Cisplatin併用療法の後方視的検討.,
第16回日本臨床腫瘍学会学術集会, 2018年7月. 中村文香, 岡本耕一, 影本開三, 村山典聡, 田中久美子, 藤野泰輝, 北村晋志, 三宮勝隆, 佐藤康史, 宮本弘志, 六車直樹, 高山哲治 :
Serrated polyposis syndromeにおける遺伝性及び発癌機序の検討.,
第14回日本消化管学会総会学術集会, 2018年2月. 岡田泰行, 木村哲夫, 岡本耕一, 中村文香, 藤野泰輝, 田中久美子, 三好人正, 三井康裕, 北村晋志, 宮本弘志, 佐藤康史, 六車直樹, 高山哲治 :
抗EGFR抗体薬治療におけるEarly tumor shrinkage(ETS)とEGFR内在化の関連について,
第88回大腸癌研究会, 2018年1月. 高岡慶史, 影本開三, 三井康裕, 田中久美子, 中村文香, 藤野泰輝, 北村晋志, 木村哲夫, 岡本耕一, 木村雅子, 仁木美也子, 宮本弘志, 六車直樹, 石川正志, 高山哲治 :
免疫チェックポイント阻害薬で加療した直腸肛門部悪性黒色腫の4例.,
第55回日本癌治療学会学術集会, 2017年10月. 藤野泰輝, 田中久美子, 中村文香, 北村晋志, 木村哲夫, 岡本耕一, 宮本弘志, 佐藤康史, 六車直樹, 高山哲治 :
大腸粘膜下層浸潤癌リンパ節転移に関わるmicroRNAの網羅的解析.,
第87回大腸癌研究会, 2017年7月. 北村晋志, 六車直樹, 松本友里, 松本早代, 岡崎潤, 髙岡遠, 村山典聡, 香川美和子, 藤野泰輝, 三好人正, 中村文香, 大塚加奈子, 宮本弘志, 岡久稔也, 高山哲治 :
内視鏡切除された直腸カルチノイド(NET-G1)の臨床経過に関する検討,
第87回日本消化器内視鏡学会総会, 2014年5月. 宮本佳彦, 六車直樹, 北村晋志, 松本友里, 松本早代, 中村文香, 髙岡遠, 藤野泰輝, 三好人正, 田中久美子, 郷司敬洋, 矢野弘美, 香川美和子, 宮本弘志, 岡久稔也, 高山哲治 :
大腸癌に対する内視鏡分子イメージング技術の開発,
第87回日本消化器内視鏡学会総会, 2014年5月. 北村晋志, 六車直樹, 松本友里, 松本早代, 岡崎潤, 髙岡遠, 香川美和子, 藤野泰輝, 三好人正, 中村文香, 田中久美子, 宮本弘志, 岡久稔也, 高山哲治 :
バレット食道癌における欧米と日本のマネジメントの相違に関する検討,
第87回日本消化器内視鏡学会総会, 2014年5月. 藤野泰輝, 大塚加奈子, 田中久美子, 中村文香, 三好人正, 香川美和子, 郷司敬洋, 髙岡遠, 矢野弘美, 北村晋志, 宮本弘志, 六車直樹, 岡久稔也, 高山哲治 :
Sessile serrated adenoma/polyp(SSA/P)の前病変としてのAberrant crypt foci(ACF)の解析,
第10回日本消化管学会総会学術集会, 2014年2月. 松本早代, 六車直樹, 松本友里, 岡崎潤, 田中久美子, 中村文香, 藤野泰輝, 三好人正, 香川美和子, 郷司敬洋, 髙岡遠, 村山典聡, 矢野弘美, 北村晋志, 宮本弘志, 岡久稔也, 高山哲治 :
内視鏡治療された直腸カルチノイド(NET-G1)の臨床経過に関する検討,
第80回大腸癌研究会, 2014年1月.

研究会・報告書: 研究者総覧に該当データはありませんでした。

特許: 研究者総覧に該当データはありませんでした。
作品: 研究者総覧に該当データはありませんでした。
補助金・競争的資金: 家族性大腸腺腫症の十二指腸腺腫に対するConnectivity Map解析に基づいた予防薬の開発 (研究課題/領域番号: 23K15011 )
Serrated polyposis症候群の原因遺伝子と発癌機序の解明 (研究課題/領域番号: 19K08471 )
研究者番号（70793743）による検索

その他: 研究者総覧に該当データはありませんでした。

研究者総覧で最新データを確認する

2024年4月26日更新

専門分野・研究分野: 研究者総覧に該当データはありませんでした。
所属学会・所属協会: 研究者総覧に該当データはありませんでした。
委員歴・役員歴: 研究者総覧に該当データはありませんでした。
受賞: 研究者総覧に該当データはありませんでした。
活動: 研究者総覧に該当データはありませんでした。

リサーチマップで最新データを確認するＪグローバルで最新データを確認する

2024年5月19日更新

2024年5月18日更新

Ｊグローバル

Jグローバル最終確認日: 2024/5/18 01:03
氏名（漢字）: 中村文香
氏名（フリガナ）: JグローバルAPIで取得できませんでした。
氏名（英字）: NAKAMURA FUMIKA
所属機関: 徳島大学大学院医歯薬学研究部

リサーチマップ

researchmap最終確認日: 2024/5/19 01:44
氏名（漢字）: 中村文香
氏名（フリガナ）: リサーチマップAPIで取得できませんでした。
氏名（英字）: NAKAMURA FUMIKA
プロフィール: リサーチマップAPIで取得できませんでした。
登録日時: 2018/11/19 12:53
更新日時: 2018/11/19 13:01
アバター画像URI: リサーチマップAPIで取得できませんでした。
ハンドル: リサーチマップAPIで取得できませんでした。
eメール: リサーチマップAPIで取得できませんでした。
eメール（その他）: リサーチマップAPIで取得できませんでした。
携帯メール: リサーチマップAPIで取得できませんでした。
性別: リサーチマップAPIで取得できませんでした。
没年月日: リサーチマップAPIで取得できませんでした。
所属ID: 0344000000
所属: 徳島大学大学院医歯薬学研究部
部署: リサーチマップAPIで取得できませんでした。
職名: リサーチマップAPIで取得できませんでした。
学位: リサーチマップAPIで取得できませんでした。
学位授与機関: リサーチマップAPIで取得できませんでした。
URL: リサーチマップAPIで取得できませんでした。
科研費研究者番号: リサーチマップAPIで取得できませんでした。
Google Analytics ID: リサーチマップAPIで取得できませんでした。
ORCID ID: リサーチマップAPIで取得できませんでした。
その他の所属ID: リサーチマップAPIで取得できませんでした。
その他の所属名: リサーチマップAPIで取得できませんでした。
その他の所属部署: リサーチマップAPIで取得できませんでした。
その他の所属職名: リサーチマップAPIで取得できませんでした。
最近のエントリー: リサーチマップAPIで取得できませんでした。
Read会員ID: リサーチマップAPIで取得できませんでした。
経歴: リサーチマップAPIで取得できませんでした。
受賞: リサーチマップAPIで取得できませんでした。
Misc: リサーチマップAPIで取得できませんでした。
論文: リサーチマップAPIで取得できませんでした。
講演・口頭発表等: リサーチマップAPIで取得できませんでした。
書籍等出版物: リサーチマップAPIで取得できませんでした。
研究キーワード: リサーチマップAPIで取得できませんでした。
研究分野: リサーチマップAPIで取得できませんでした。
所属学協会: リサーチマップAPIで取得できませんでした。
担当経験のある科目: リサーチマップAPIで取得できませんでした。
その他: リサーチマップAPIで取得できませんでした。
Works: リサーチマップAPIで取得できませんでした。
特許: リサーチマップAPIで取得できませんでした。
学歴: リサーチマップAPIで取得できませんでした。
委員歴: リサーチマップAPIで取得できませんでした。
社会貢献活動: リサーチマップAPIで取得できませんでした。

ＫＡＫＥＮで最新データを確認する

2024年5月18日更新

研究者番号: 70793743

所属（現在）: 2024/4/1 : 徳島大学, 病院, 特任助教

所属（過去の研究課題 情報に基づく）*注記: 2023/4/1 : 徳島大学, 病院, 特任助教
2019/4/1 – 2021/4/1 : 徳島大学, 病院, 特任助教

審査区分/研究分野

研究代表者

小区分53010:消化器内科学関連

研究代表者以外

小区分53010:消化器内科学関連

キーワード

研究代表者

家族性大腸腺腫症 / 十二指腸腺腫 / Connectivity Map / オルガノイド / 化学予防

研究代表者以外

SPS / メチル化 / 大腸癌 / 腺腫 / 鋸歯状ポリープ / 鋸歯状ポリポーシス症候群 / serrated pathway / BRAF

研究課題研究成果共同研究者

「研究課題をさがす」で表示
テキスト（CSV）で出力

テキスト（CSV）で出力

注目研究はありません。

研究者を探す

中村 文香

Ｊグローバル

リサーチマップ

研究代表者

研究代表者以外

研究代表者

研究代表者以外

中村文香